Javascript must be enabled to continue!
Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign
View through CrossRef
A 3D structure-based pharmacophore model built for bromodomain-containing protein 4 (BRD4) is reported here, specifically developed for investigating and identifying the key structural features of the (+)-JQ1 known inhibitor within the BRD4 binding site. Using this pharmacophore model, 273 synthesized and purchased compounds previously considered for other targets but yielding poor results were screened in a drug repositioning campaign. Subsequently, only six compounds showed potential as BRD4 binders and were subjected to further biophysical and biochemical assays. Compounds 2, 5, and 6 showed high affinity for BRD4, with IC50 values of 0.60 ± 0.25 µM, 3.46 ± 1.22 µM, and 4.66 ± 0.52 µM, respectively. Additionally, these compounds were tested against two other bromodomains, BRD3 and BRD9, and two of them showed high selectivity for BRD4. The reported 3D structure-based pharmacophore model proves to be a straightforward and useful tool for selecting novel BRD4 ligands.
Title: Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign
Description:
A 3D structure-based pharmacophore model built for bromodomain-containing protein 4 (BRD4) is reported here, specifically developed for investigating and identifying the key structural features of the (+)-JQ1 known inhibitor within the BRD4 binding site.
Using this pharmacophore model, 273 synthesized and purchased compounds previously considered for other targets but yielding poor results were screened in a drug repositioning campaign.
Subsequently, only six compounds showed potential as BRD4 binders and were subjected to further biophysical and biochemical assays.
Compounds 2, 5, and 6 showed high affinity for BRD4, with IC50 values of 0.
60 ± 0.
25 µM, 3.
46 ± 1.
22 µM, and 4.
66 ± 0.
52 µM, respectively.
Additionally, these compounds were tested against two other bromodomains, BRD3 and BRD9, and two of them showed high selectivity for BRD4.
The reported 3D structure-based pharmacophore model proves to be a straightforward and useful tool for selecting novel BRD4 ligands.
Related Results
BRD4 isoforms have distinct roles in tumor progression and metastasis in embryonal rhabdomyosarcoma
BRD4 isoforms have distinct roles in tumor progression and metastasis in embryonal rhabdomyosarcoma
ABSTRACTBRD4, a bromodomain and extraterminal (BET) protein, is deregulated in multiple cancers and has emerged as a promising drug target. However, the function of the two main BR...
Abstract 971: Chaperone-mediated protein degradation (CHAMP): A novel technology for tumor-targeted protein degradation
Abstract 971: Chaperone-mediated protein degradation (CHAMP): A novel technology for tumor-targeted protein degradation
Abstract
The HSP90 chaperone mediates folding of many important client proteins and mutated oncoproteins, but can also direct its substrates towards degradation by t...
Studies on Gene Enhancer with KSHV mini-chromatin
Studies on Gene Enhancer with KSHV mini-chromatin
Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) genome contains a terminal repeats (TR) sequence. Previous studies demonstrated that KSHV...
Hepatic BRD4 Is Upregulated in Liver Fibrosis of Various Etiologies and Positively Correlated to Fibrotic Severity
Hepatic BRD4 Is Upregulated in Liver Fibrosis of Various Etiologies and Positively Correlated to Fibrotic Severity
Bromodomain-containing protein 4 (BRD4) has been implicated to play a regulatory role in fibrogenic gene expression in animal models of liver fibrosis. The potential role of BRD4 i...
Abstract 1528: Forecasting novel therapies by understanding the role BRD4 in regulating the Notch3 signaling in ovarian cancer
Abstract 1528: Forecasting novel therapies by understanding the role BRD4 in regulating the Notch3 signaling in ovarian cancer
Abstract
Advances in cancer research have led to the rapid development of novel drug therapies designed for optimal personalized patient care. Despite this surge of ...
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Background:
Currently, cancer continues being a dramatically increasing and serious
threat to public health. Although many anti-tumor agents have been developed in recent years, th...
Abstract 1816: BRD4 inhibitor I-BET151 sensitizes glioblastoma to radiotherapy by suppressing super-enhancer-driven COL1A1
Abstract 1816: BRD4 inhibitor I-BET151 sensitizes glioblastoma to radiotherapy by suppressing super-enhancer-driven COL1A1
Abstract
Glioblastoma (GBM) is a highly aggressive and fatal brain tumor typically treated with high-dose radiation (RT) and chemotherapy. However, the limited RT ef...
IDENTIFICATION OF NEW CYCLOOXYGENASE-2 SELECTIVE INHIBITORS VIA VIRTUAL SCREENING AND COMPLEX-BASED PHARMACOPHORE MAPPING
IDENTIFICATION OF NEW CYCLOOXYGENASE-2 SELECTIVE INHIBITORS VIA VIRTUAL SCREENING AND COMPLEX-BASED PHARMACOPHORE MAPPING
Background: New and effective COX-2-targeted medications may cure cancer, inflammation, and other disorders.It’s difficult to produce druggable site inhibitors for target protein i...

